We are live on
!
Find out more
AWM
Aevitas Wealth Management Portfolio holdings
AUM
$169M
1-Year Est. Return
9.55%
This Fund
S&P 500
This Quarter
Est. Return
+7.25%
1 Year Est. Return
-9.55%
3 Year Est. Return
+36.41%
5 Year Est. Return
+72.53%
10 Year Est. Return
–
AUM
$110M
AUM Growth
+$7.71M
(+7.5%)
Cap. Flow
+$1.15M
Cap. Flow
% of AUM
1.05%
Top 10 Holdings %
Top 10 Hldgs %
29.89%
Holding
461
New
33
Increased
162
Reduced
63
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$511K |
| 2 |
Vanguard Value ETF
VTV
|
+$489K |
| 3 |
PepsiCo
PEP
|
+$236K |
| 4 |
Vanguard Small-Cap ETF
VB
|
+$129K |
| 5 |
NVIDIA
NVDA
|
+$78K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$262K |
| 2 |
Voyager Therapeutics
VYGR
|
+$211K |
| 3 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$188K |
| 4 |
BSCN
Invesco BulletShares 2023 Corporate Bond ETF
BSCN
|
+$161K |
| 5 |
BSCM
Invesco BulletShares 2022 Corporate Bond ETF
BSCM
|
+$92.7K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 12.78% |
| 2 | Technology | 12.74% |
| 3 | Consumer Staples | 11.44% |
| 4 | Consumer Discretionary | 8.84% |
| 5 | Financials | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDR
451
DELISTED
McDermott International
MDR
| $1K | ﹤0.01% |
31
| – | – |
|
|
NAVB
452
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $1K | ﹤0.01% |
300
| – | – |
|
|
CRC
453
DELISTED
California Resources Corporation
CRC
| $1K | ﹤0.01% |
+11
| New | +$423 |
|
|
HR
454
DELISTED
Healthcare Realty Trust Incorporated
HR
| $1K | ﹤0.01% |
50
| – | – |
|
455
Bausch Health
BHC
$1.69B
| – | – |
-1,990
| Closed | -$46K |
|
456
Elevance Health
ELV
$83.7B
| – | – |
-100
| Closed | -$24K |
|
457
Snap
SNAP
$8.02B
| – | – |
-48
| Closed | -$1K |
|
|
PTLA
458
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-100
| Closed | -$4K |
|
|
APU
459
DELISTED
AmeriGas Partners, L.P.
APU
| – | – |
-500
| Closed | -$21K |
|
|
WGL
460
DELISTED
Wgl Holdings
WGL
| – | – |
-800
| Closed | -$71K |
|
|
CAVM
461
DELISTED
Cavium, Inc.
CAVM
| – | – |
-50
| Closed | -$4K |
|
Similar funds
CCM
BA
BFS
RCC
S
RCA
SCM
WWA
Aevitas Wealth Management's Q3 2018 Portfolio in Review
As of Q3 2018, Aevitas Wealth Management held 461 positions worth $110M, up 7.5% from $103M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Aevitas Wealth Management's Q3 2018 filing shows 33 new, 162 increased, 63 reduced and 7 closed positions. Its largest new stake was Weyerhaeuser: 1,110 shares worth $36K. The largest sale was CRISPR Therapeutics, an estimated $262K.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.
- Aevitas Wealth Management's largest Q3 2018 buy was Weyerhaeuser: 1,110 shares worth $36K.
- Aevitas Wealth Management added most to Microsoft in Q3 2018, an estimated $511K increase.
- Aevitas Wealth Management's biggest Q3 2018 reduction was CRISPR Therapeutics, cutting an estimated $262K.
- Aevitas Wealth Management fully exited Wgl Holdings in Q3 2018, selling an estimated $71K.
- Aevitas Wealth Management's ten largest holdings make up 30% of its $110M portfolio in Q3 2018.
- Aevitas Wealth Management opened 33 new positions and closed 7 in Q3 2018.
- Aevitas Wealth Management's portfolio value rose 7.5% quarter-over-quarter to $110M.
Based on Aevitas Wealth Management's 13F filing for Q3 2018, filed 14 Nov 2018.